These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 26526983)

  • 1. The pharmacokinetics and safety of idelalisib in subjects with severe renal impairment.
    Jin F; Robeson M; Zhou H; Hisoire G; Ramanathan S
    Cancer Chemother Pharmacol; 2015 Dec; 76(6):1133-41. PubMed ID: 26526983
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The pharmacokinetics and safety of idelalisib in subjects with moderate or severe hepatic impairment.
    Jin F; Robeson M; Zhou H; Hisoire G; Ramanathan S
    J Clin Pharmacol; 2015 Aug; 55(8):944-52. PubMed ID: 25821156
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population pharmacokinetic modeling of idelalisib, a novel PI3Kδ inhibitor, in healthy subjects and patients with hematologic malignancies.
    Jin F; Gao Y; Zhou H; Fang L; Li X; Ramanathan S
    Cancer Chemother Pharmacol; 2016 Jan; 77(1):89-98. PubMed ID: 26645408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical drug interaction profile of idelalisib in healthy subjects.
    Jin F; Robeson M; Zhou H; Moyer C; Wilbert S; Murray B; Ramanathan S
    J Clin Pharmacol; 2015 Aug; 55(8):909-19. PubMed ID: 25760671
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Pharmacokinetic and Pharmacodynamic Profile of Idelalisib.
    Ramanathan S; Jin F; Sharma S; Kearney BP
    Clin Pharmacokinet; 2016 Jan; 55(1):33-45. PubMed ID: 26242379
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Renal Impairment on the Pharmacokinetics of Pradigastat, a Novel Diacylglycerol Acyltransferase1 (DGAT1) Inhibitor.
    Mita S; Meyers D; Pal P; Lin T; Majumdar T; Rebello S; Sunkara G; Chen J
    Clin Pharmacokinet; 2015 Jul; 54(7):751-60. PubMed ID: 25627776
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of the effects of renal impairment on the pharmacokinetic profile of laninamivir, a novel neuraminidase inhibitor, after a single inhaled dose of its Prodrug, CS-8958.
    Ishizuka H; Yoshiba S; Yoshihara K; Okabe H
    J Clin Pharmacol; 2011 Feb; 51(2):243-51. PubMed ID: 20197485
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study.
    Stangier J; Rathgen K; Stähle H; Mazur D
    Clin Pharmacokinet; 2010 Apr; 49(4):259-68. PubMed ID: 20214409
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of severe renal impairment on the pharmacokinetics of clazosentan.
    Bruderer S; Sasu B; Tsvitbaum N; Dingemanse J
    J Clin Pharmacol; 2011 Mar; 51(3):413-21. PubMed ID: 20926750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of adverse events associated with idelalisib treatment: expert panel opinion.
    Coutré SE; Barrientos JC; Brown JR; de Vos S; Furman RR; Keating MJ; Li D; O'Brien SM; Pagel JM; Poleski MH; Sharman JP; Yao NS; Zelenetz AD
    Leuk Lymphoma; 2015; 56(10):2779-86. PubMed ID: 25726955
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and imaging properties of Gd-EOB-DTPA in patients with hepatic and renal impairment.
    Gschwend S; Ebert W; Schultze-Mosgau M; Breuer J
    Invest Radiol; 2011 Sep; 46(9):556-66. PubMed ID: 21623212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of pharmacokinetics and safety of ponatinib in subjects with chronic hepatic impairment and matched healthy subjects.
    Narasimhan NI; Dorer DJ; Davis J; Turner CD; Marbury TC; Sonnichsen D
    Cancer Chemother Pharmacol; 2014 Aug; 74(2):341-8. PubMed ID: 24934866
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effects of degree of hepatic or renal impairment on the pharmacokinetics of exemestane in postmenopausal women.
    Jannuzzo MG; Poggesi I; Spinelli R; Rocchetti M; Cicioni P; Buchan P
    Cancer Chemother Pharmacol; 2004 Jun; 53(6):475-81. PubMed ID: 15014897
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Phase I, Open-Label, Parallel-Group, Single-Dose Trial of the Pharmacokinetics, Safety, and Tolerability of Cannabidiol in Subjects with Mild to Severe Renal Impairment.
    Tayo B; Taylor L; Sahebkar F; Morrison G
    Clin Pharmacokinet; 2020 Jun; 59(6):747-755. PubMed ID: 31802404
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I, open-label, multicenter study to evaluate the pharmacokinetics and safety of oral panobinostat in patients with advanced solid tumors and varying degrees of renal function.
    Sharma S; Witteveen PO; Lolkema MP; Hess D; Gelderblom H; Hussain SA; Porro MG; Waldron E; Valera SZ; Mu S
    Cancer Chemother Pharmacol; 2015 Jan; 75(1):87-95. PubMed ID: 25377157
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics, safety, and tolerability of maraviroc in HIV-negative subjects with impaired renal function.
    Vourvahis M; Fang J; Checchio T; Milton A; Weatherley B; McFadyen L; Heera J
    HIV Clin Trials; 2013; 14(3):99-109. PubMed ID: 23835512
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics and safety of single-dose ribavirin in patients with chronic renal impairment.
    Gupta SK; Kantesaria B; Glue P
    Drug Discov Ther; 2013 Aug; 7(4):158-63. PubMed ID: 24071578
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics, Safety, and Tolerability of Intravenous Durlobactam and Sulbactam in Subjects with Renal Impairment and Healthy Matched Control Subjects.
    O'Donnell J; Preston RA; Mamikonyan G; Stone E; Isaacs R
    Antimicrob Agents Chemother; 2019 Sep; 63(9):. PubMed ID: 31307978
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of Renal Impairment on the Pharmacokinetics of Afatinib: An Open-Label, Single-Dose Study.
    Wiebe S; Schnell D; Külzer R; Gansser D; Weber A; Wallenstein G; Halabi A; Conrad A; Wind S
    Eur J Drug Metab Pharmacokinet; 2017 Jun; 42(3):461-469. PubMed ID: 27436099
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and safety of ebastine in healthy subjects and patients with renal impairment.
    Noveck RJ; Preston RA; Swan SK
    Clin Pharmacokinet; 2007; 46(6):525-34. PubMed ID: 17518511
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.